| abstract |
of the Invention The present invention provides conjugates containing a (i) TGF-β antagonist, such as a TGF-β antagonist antibody, protein, peptide, or small molecule capable of inhibiting TGF-β signaling, bound to (ii) a bone-targeting moiety. The bone targeting moiety localizes the TGF-β antagonist to osseous tissue. 0 The conjugates described herein provide a therapeutic paradigm for the treatment of various diseases associated with elevated TGF-β signaling and elevated bone turnover, such as osteogenesis imperfecta and other bone pathologies. |